Travere Therapeutics, INC 8-K filings

NASDAQ

23 Feb 2024

TVTX

8-K: Travere Therapeutics Receives Positive CHMP Opinion for Sparsentan in Europe

The European Medicines Agency's CHMP has recommended conditional approval for Travere Therapeutics' sparsentan to treat adults with primary IgA nephropathy.

NASDAQ

15 Feb 2024

TVTX

Travere Therapeutics, INC

8-K: Travere Therapeutics Reports Strong 2023 Results and Advances Pipeline

Travere Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting growth in FILSPARI sales and progress in its clinical programs.